Le Lézard
Classified in: Health, Science and technology, Covid-19 virus

CRISPR Technology Market Report 2024, with Profiles of Major Players Agilent Technologies, Beam Therapeutics, Caribou Biosciences, Crispr Therapeutics, Danaher, Genscript, Lonza and More - ResearchAndMarkets.com


The "CRISPR Technology Market" report has been added to ResearchAndMarkets.com's offering.

The CRISPR Technology Market was valued at USD 2024 in 2029, and is expected to reach USD 3.8 billion by 7.5 billion, rising at a CAGR of 14.4%.

This report on CRISPR technology provides market projections for 2029 and analyzes the market for CRISPR technology by application and end user. Applications covered include drug development, agriculture, diagnostics and others. End users include biotechnology and pharmaceutical companies, academics and government research institutes, and contract research organizations.

The report includes:

Key Attributes:

Report Attribute Details
No. of Pages 122
Forecast Period 2024 - 2029
Estimated Market Value (USD) in 2024 $3.8 Billion
Forecasted Market Value (USD) by 2029 $7.5 Billion
Compound Annual Growth Rate 14.4%
Regions Covered Global

Key Topics Covered:

Chapter 1 Executive Summary

Chapter 2 Market Overview

Chapter 3 Market Dynamics

Chapter 4 Emerging Technologies and Developments

Chapter 5 Market Segmentation Analysis

Chapter 6 Competitive Intelligence

Chapter 7 Sustainability in CRISPR Technology: An ESG Perspective

Company Profiles

For more information about this report visit https://www.researchandmarkets.com/r/r5m0hq

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.


These press releases may also interest you

at 12:55
Vertex Pharmaceuticals Incorporated today announced longer-term data for CASGEVYtm (exagamglogene autotemcel) from global clinical trials in people with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). CASGEVY is the...

at 12:35
Kite, a Gilead Company , today announced findings from three new analyses for Yescarta® (axicabtagene ciloleucel) that demonstrate improved outcomes for people living with relapsed or refractory (R/R) large B-cell lymphoma (LBCL), which were...

at 12:35
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today data from a five-year follow-up of the pivotal Phase III POLARIX study evaluating Polivy® (polatuzumab vedotin-piiq) in combination with Rituxan® (rituximab),...

at 12:35
bluebird bio, Inc. today announced new and updated data from LYFGENIAtm (lovotobegligene autotemcel, or lovo-cel) gene therapy for patients with sickle cell disease who have a history of vaso-occlusive events (VOEs). The data will be presented at...

at 12:33
Johnson & Johnson today announced new frontline data featuring TECVAYLI® (teclistamab-cqyv) from two investigational studies in patients with newly diagnosed multiple myeloma (NDMM) in induction and maintenance settings. The MajesTEC-5 (Abstract...

at 12:30
- Study clarifies impact of CAR T-cell therapy in transformed follicular...



News published on and distributed by: